AI Summary
Thinking
Thinking
We reviewed 3 live results for subclinical rejection and narrowed them down to the 3 options that look most worth comparing first.
The options are TruGraf Kidney, Takfa 0.5mg Capsule and Prospera.
Source: Transplant Genomics
Description
TruGraf Kidney by Transplant Genomics is a non-invasive peripheral blood gene expression biomarker test designed for serial surveillance of kidney transplant recipients with stable renal function. Utilizing microfluidic PCR technology, the diagnostic assay measures differentially expressed genes to assess immune quiescence and rule out silent subclinical acute rejection more than 90 days post-transplant without requiring invasive protocol biopsies.
Best for
Kidney transplant recipients, Transplant clinicians, Serial post-transplant graft health surveillance and Ruling out subclinical acute rejection without biopsy
Rate this product
Source: Phoenix Exim
Description
Takfa 0.5mg Capsule is an oral immunosuppressive prescription medicine containing tacrolimus 0.5mg, marketed by Intas Pharmaceuticals Ltd. and supplied internationally by Phoenix Exim. It functions as a calcineurin inhibitor to reduce immune-system activity and help prevent organ rejection in kidney, liver, and heart transplant recipients.
Best for
Transplant patients and Preventing organ rejection following kidney, liver, or heart transplant
Rate this product
Source: Natera
Description
Prospera by Natera is a donor-derived cell-free DNA (dd-cfDNA) transplant rejection assessment test designed for kidney transplant recipients. Requiring a simple blood draw, the diagnostic test evaluates the risk of rejection, identifying antibody-mediated and T cell-mediated rejection ahead of biopsy confirmation to help clinicians protect transplanted kidneys. Covered by Medicare, it integrates with Natera's Organ Health provider portal for surveillance and clinically indicated monitoring.
Best for
kidney transplant recipients, transplant clinicians, kidney transplant rejection risk assessment and post-transplant surveillance
Rate this product
| Compare | #1TruGraf Kidney | #2Takfa 0.5mg Capsule | #3Prospera |
|---|---|---|---|
| Source | Transplant Genomics | Phoenix Exim | Natera |
| Description | TruGraf Kidney by Transplant Genomics is a non-invasive peripheral blood gene expression biomarker test designed for serial surveillance of kidney transplant recipients with stable renal function. Utilizing microfluidic PCR technology, the diagnostic assay measures differentially expressed genes to assess immune quiescence and rule out silent subclinical acute rejection more than 90 days post-transplant without requiring invasive protocol biopsies. | Takfa 0.5mg Capsule is an oral immunosuppressive prescription medicine containing tacrolimus 0.5mg, marketed by Intas Pharmaceuticals Ltd. and supplied internationally by Phoenix Exim. It functions as a calcineurin inhibitor to reduce immune-system activity and help prevent organ rejection in kidney, liver, and heart transplant recipients. | Prospera by Natera is a donor-derived cell-free DNA (dd-cfDNA) transplant rejection assessment test designed for kidney transplant recipients. Requiring a simple blood draw, the diagnostic test evaluates the risk of rejection, identifying antibody-mediated and T cell-mediated rejection ahead of biopsy confirmation to help clinicians protect transplanted kidneys. Covered by Medicare, it integrates with Natera's Organ Health provider portal for surveillance and clinically indicated monitoring. |
| Best for | Kidney transplant recipients, Transplant clinicians, Serial post-transplant graft health surveillance and Ruling out subclinical acute rejection without biopsy | Transplant patients and Preventing organ rejection following kidney, liver, or heart transplant | kidney transplant recipients, transplant clinicians, kidney transplant rejection risk assessment and post-transplant surveillance |
| Action | Transplant Genomics | Phoenix Exim | Natera |
| Rate this product |
"TruGraf Kidney from Transplant Genomics."
Note: TopFind AI compiles product and service information for general comparison purposes only.